An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2]

Value in Health

Volumn 21, Issue 2, 2018, Pages 124-130

  Garrison, Louis P ^a   Pauly, Mark V ^b   Willke, Richard J ^c   Neumann, Peter J ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c International Society for Pharmacoeconomics and Outcomes Research   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

cost effectiveness analysis; decision context; perspective; value

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; PRIORITY JOURNAL; ADVISORY COMMITTEE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PROCEDURES; UNITED STATES;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, HEALTH; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES;

EID: 85042284198     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.12.006     Document Type: Article

References (23)

1. Neumann, P.J., Willke, R.J., Garrison, L.P., A health economics approach to US value assessment frameworks—introduction: an ISPOR Special Task Force report [1]. Value Health 21 (2018), 119–123.
2. Neumann, P.J., Sanders, G.D., Russell, L.B., et al. Cost-Effectiveness in Health and Medicine. 2016, Oxford University Press, New York, NY.
3. Camejo, R.R., Miraldo, M., Rutten, F., Cost-effectiveness and dynamic efficiency: Does the solution lie within?. Value Health 20 (2017), 240–243.
4. Garber, A.M., Phelps, C.E., Economic foundations of cost-effectiveness analysis. J Health Econ 16 (1997), 1–31.
5. McCabe, C.K., Claxton, K., Culyer, A.J., The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics 26 (2016), 733–744.
6. Sculpher, M., Claxton, K., Pearson, S.D., Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health 20 (2017), 234–239.
7. Brouwer, W.B., Culyer, A.J., van Exel, N.J., Rutten, F.F., Welfarism vs. extra-welfarism. J Health Econ 27 (2008), 325–338.
8. Drummond, M.F., Sculpher, M., Claxton, K., et al. Methods for the Economic Evaluation of Health Care Programmes, 4th ed., 2015, Oxford University Press, Oxford, UK.
9. Sanders, G.D., Neumann, P.J., Basu, A., et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 316 (2016), 1093–1103.
10. Schnipper, L.E., Davidson, H.E., Wollins, D.S., et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34 (2016), 2925–2934.
11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) with NCCN Evidence Blocks™. Available from: www.nccn.org/evidenceblocks/. [Accessed December 4, 2016].
12. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
13. Memorial Sloan Kettering Cancer Center. DrugAbacus FAQs. Available from: www.drugabacus.org/faqs. [Accessed December 4, 2016].
14. Lakdawalla, D.N., Doshi, J.A., Garrison, L.P., Phelps, C.E., Basu, A., Danzon, P.M., Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]. Value Health 21 (2018), 131–139.
15. Simon, H.R., A behavioral model of rational choice. Q J Econ 69 (1955), 99–118.
16. Tversky, A., Kahneman, D., Judgment under uncertainty: heuristics and biases. Science 185 (1974), 1124–1131.
17. Jensen, M.C., Meckling, W.H., Theory of the firm: managerial behavior, agency costs and ownership structure. J Financ Econ 3 (1976), 305–360.
18. Fuchs, V.R., The supply of surgeons and the demand for operations. J Hum Resour 13:Suppl. (1978), 35–56.
19. Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., Towse, A., Danzon, P.M., Approaches to aggregation and decision making—a health economics approach: an ISPOR Special Task Force report [5]. Value Health 21 (2018), 146–154.
20. Minhas, R., Moon, J.C., The Office of Fair Trading report: a prescription for value-based drug pricing. J R Soc Med 100 (2007), 216–218.
21. Raftery, J.P., NICE's cost-effectiveness range: Should it be lowered?. Pharmacoeconomics 32 (2014), 613–615.
22. Pauly, M.V., The questionable economic case for value-based drug pricing in market health systems. Value Health 20 (2017), 278–282.
23. Drummond, M., Clinical guidelines: A NICE way to introduce cost-effectiveness considerations?. Value Health 19 (2016), 525–530.